Deciphera Pharmaceuticals, LLC is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts, with research facilities in Lawrence, Kansas. A wholly owned subsidiary of Ono Pharmaceutical Co., Ltd. since 2024, it focuses on discovering, developing, and commercializing kinase inhibitor medicines, primarily for cancer patients.
Leveraging its proprietary switch-control kinase inhibitor platform, Deciphera targets oncology, neurology, and immunology indications with high unmet needs. Key approved products include QINLOCK (ripretinib), a treatment for advanced gastrointestinal stromal tumor (GIST) in patients previously treated with three or more kinase inhibitors, approved in the US and EU; and ROMVIMZA (vimseltinib), for symptomatic tenosynovial giant cell tumor (TGCT) where surgery is not viable, approved in the US and EU.
The company maintains a pipeline of candidates such as tirabrutinib for relapsed/refractory primary central nervous system lymphoma and others addressing GIST, polycythemia vera, and more. Founded in 2003, Deciphera operates commercial platforms in the US and Europe.
Also known as Deciphera Pharmaceuticals, Inc..
Brings 20+ years' international biotech leadership in oncology, will oversee European and emerging markets commercialization from Zug, focusing on launch execution and scaling operations.
